The phenotypic spectrum of GABRG2 variants extends to the pharmacoresistant epilepsies, including Dravet syndrome and developmental epileptic encephalopathies (DEEs) (Harkin et al., 2002; Shen et al., 2017; Oyrer et al., 2018). This evidence concerns the gene GABRG2 and epilepsy.